| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
|
Medicine details |
|
| Medicine name | talimogene laherparepvec (Imlygic®) |
| Formulation | solution for injection |
| Reference number | 544 |
| Indication | Treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease |
| Company | Amgen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 27/11/2015 |
| NICE guidance | TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |